FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113955549> ?p ?o ?g. }

• W2113955549 abstract "Background This is the second update of a Cochrane review that was first published in 2009, Issue 1. Gestational trophoblastic neoplasia (GTN) is a rare but curable disease arising in the fetal chorion during pregnancy. Most women with low‐risk GTN will be cured by evacuation of the uterus with or without single‐agent chemotherapy. However, chemotherapy regimens vary between treatment centres worldwide and the comparable benefits and risks of these different regimens are unclear. Objectives To determine the efficacy and safety of first‐line chemotherapy in the treatment of low‐risk GTN. Search methods We electronically searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase in September 2008, February 2012, and January 2016. In addition, we searched online trial registers for protocols and ongoing trials. Selection criteria For the original review, we included randomised controlled trials (RCTs), quasi‐RCTs and non‐RCTs that compared first‐line chemotherapy for the treatment of low‐risk GTN. For this updated versions of the review, we included only RCTs. Data collection and analysis Two review authors independently assessed studies for inclusion and extracted data to a pre‐designed data extraction form. Meta‐analysis was performed using the random‐effects model. Main results We included seven RCTs (667 women) in this updated review. Most studies were at a low or moderate risk of bias and all compared methotrexate with actinomycin D. Three studies compared weekly intramuscular (IM) methotrexate with bi‐weekly pulsed intravenous (IV) actinomycin D (393 women), one study compared five‐day IM methotrexate with bi‐weekly pulsed IV actinomycin D (75 women), one study compared eight‐day IM methotrexate‐folinic acid (MTX‐FA) with five‐day IV actinomycin D (49 women), and one study compared eight‐day IM MTX‐FA with bi‐weekly pulsed IV actinomycin D. One study contributed no data. Moderate‐certainty evidence indicates that actinomycin D is probably more likely to lead to primary cure than methotrexate (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.57 to 0.75; six trials, 577 participants; I2 = 26%), and first‐line methotrexate treatment is probably more likely to fail than actinomycin D treatment (RR 3.55, 95% CI 1.81 to 6.95; six trials, 577 participants; I2 = 61%; moderate‐certainty evidence) Low‐certainty evidence suggests that there may be little or no difference between methotrexate and actinomycin D treatment with respect to nausea (four studies, 466 women; RR 0.61, 95% CI 0.29 to 1.26) or any of the other individual side‐effects reported, although data for all of these outcomes were insufficient and too inconsistent to be conclusive. Low‐certainty evidence suggests that there may be little or no difference in the risk of severe adverse events (SAEs) between the groups overall (five studies, 515 women; RR 0.35, 95% CI 0.08 to 1.66; I² = 60%); however, the direction of effect favours methotrexate and more evidence is needed. Furthermore, evidence from subgroup analyses suggests that actinomycin D may be associated with a greater risk of SAEs than methotrexate (low‐certainty evidence). We found no evidence on the effect of these treatments on future fertility. Authors' conclusions Actinomycin D is probably more likely to achieve a primary cure in women with low‐risk GTN, and less likely to result in treatment failure, than a methotrexate regimen. There may be little or no difference between the pulsed actinomycin D regimen and the methotrexate regimen with regard to side‐effects. However, actinomycin D may be associated with a greater risk of severe adverse events (SAEs) than a methotrexate regimen. Higher‐certainty evidence is still needed on treating low‐risk GTN and the four ongoing trials are likely to make a significant contribution to this field. Given the variety of treatment regimens, findings from these trials could facilitate a network meta‐analysis in the next version of this review to help women and clinicians determine the best treatment options for low‐risk GTN." @default.
• W2113955549 created "2016-06-24" @default.
• W2113955549 creator A5003520704 @default.
• W2113955549 creator A5024050303 @default.
• W2113955549 creator A5055280881 @default.
• W2113955549 creator A5056335210 @default.
• W2113955549 creator A5084423190 @default.
• W2113955549 date "2016-06-09" @default.
• W2113955549 modified "2023-10-06" @default.
• W2113955549 title "First-line chemotherapy in low-risk gestational trophoblastic neoplasia" @default.
• W2113955549 cites W105522267 @default.
• W2113955549 cites W1519509561 @default.
• W2113955549 cites W1523520347 @default.
• W2113955549 cites W1546839557 @default.
• W2113955549 cites W1566297368 @default.
• W2113955549 cites W1574133251 @default.
• W2113955549 cites W1595184853 @default.
• W2113955549 cites W165377477 @default.
• W2113955549 cites W1968159849 @default.
• W2113955549 cites W1968373373 @default.
• W2113955549 cites W1976428100 @default.
• W2113955549 cites W1978768134 @default.
• W2113955549 cites W1981256649 @default.
• W2113955549 cites W1981630094 @default.
• W2113955549 cites W1983227738 @default.
• W2113955549 cites W1983758373 @default.
• W2113955549 cites W1985264904 @default.
• W2113955549 cites W1995694389 @default.
• W2113955549 cites W1996258414 @default.
• W2113955549 cites W2000817015 @default.
• W2113955549 cites W2006702385 @default.
• W2113955549 cites W2010443570 @default.
• W2113955549 cites W2022787659 @default.
• W2113955549 cites W2028063483 @default.
• W2113955549 cites W2031374937 @default.
• W2113955549 cites W2034384523 @default.
• W2113955549 cites W2039310913 @default.
• W2113955549 cites W2041876783 @default.
• W2113955549 cites W2042920161 @default.
• W2113955549 cites W2044229996 @default.
• W2113955549 cites W2049526287 @default.
• W2113955549 cites W2051629412 @default.
• W2113955549 cites W2052435992 @default.
• W2113955549 cites W2059479791 @default.
• W2113955549 cites W2063756180 @default.
• W2113955549 cites W2067511230 @default.
• W2113955549 cites W2074936753 @default.
• W2113955549 cites W2075665293 @default.
• W2113955549 cites W2078820773 @default.
• W2113955549 cites W2080876162 @default.
• W2113955549 cites W2093685655 @default.
• W2113955549 cites W2093815392 @default.
• W2113955549 cites W2106612113 @default.
• W2113955549 cites W2107328434 @default.
• W2113955549 cites W2111046733 @default.
• W2113955549 cites W2113955549 @default.
• W2113955549 cites W2120150055 @default.
• W2113955549 cites W2125435699 @default.
• W2113955549 cites W2139151415 @default.
• W2113955549 cites W2149331758 @default.
• W2113955549 cites W2154235620 @default.
• W2113955549 cites W2160168356 @default.
• W2113955549 cites W2297838724 @default.
• W2113955549 cites W2402037648 @default.
• W2113955549 cites W2417655759 @default.
• W2113955549 cites W4206066015 @default.
• W2113955549 cites W4237491269 @default.
• W2113955549 cites W4252434684 @default.
• W2113955549 cites W4255517744 @default.
• W2113955549 cites W4300450595 @default.
• W2113955549 cites W72848393 @default.
• W2113955549 cites W938634704 @default.
• W2113955549 doi "https://doi.org/10.1002/14651858.cd007102.pub4" @default.
• W2113955549 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6768658" @default.
• W2113955549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27281496" @default.
• W2113955549 hasPublicationYear "2016" @default.
• W2113955549 type Work @default.
• W2113955549 sameAs 2113955549 @default.
• W2113955549 citedByCount "63" @default.
• W2113955549 countsByYear W21139555492012 @default.
• W2113955549 countsByYear W21139555492013 @default.
• W2113955549 countsByYear W21139555492014 @default.
• W2113955549 countsByYear W21139555492015 @default.
• W2113955549 countsByYear W21139555492016 @default.
• W2113955549 countsByYear W21139555492017 @default.
• W2113955549 countsByYear W21139555492018 @default.
• W2113955549 countsByYear W21139555492019 @default.
• W2113955549 countsByYear W21139555492020 @default.
• W2113955549 countsByYear W21139555492021 @default.
• W2113955549 countsByYear W21139555492022 @default.
• W2113955549 countsByYear W21139555492023 @default.
• W2113955549 crossrefType "journal-article" @default.
• W2113955549 hasAuthorship W2113955549A5003520704 @default.
• W2113955549 hasAuthorship W2113955549A5024050303 @default.
• W2113955549 hasAuthorship W2113955549A5055280881 @default.
• W2113955549 hasAuthorship W2113955549A5056335210 @default.
• W2113955549 hasAuthorship W2113955549A5084423190 @default.
• W2113955549 hasBestOaLocation W21139555492 @default.
• W2113955549 hasConcept C126322002 @default.
• W2113955549 hasConcept C131872663 @default.

• next